| Recruiting | A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors NCT07029399 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer NCT05902988 | Volastra Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma NCT05619913 | Australia New Zealand Gynaecological Oncology Group | Phase 2 |
| Terminated | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors NCT05229601 | HiFiBiO Therapeutics | Phase 1 |
| Active Not Recruiting | A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma NCT05147558 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Express NCT04802876 | SOLTI Breast Cancer Research Group | Phase 2 |
| Completed | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) NCT03694262 | Medical College of Wisconsin | Phase 2 |
| Withdrawn | Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With NCT03902379 | Rutgers, The State University of New Jersey | N/A |
| Terminated | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer NCT01367301 | Albert Einstein College of Medicine | N/A |
| Completed | Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer NCT01247571 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer NCT01168232 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus NCT01061606 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Isl NCT01010126 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Ut NCT00954174 | GOG Foundation | Phase 3 |
| Completed | Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045 NCT00687687 | Sanofi | Phase 2 |
| Completed | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma NCT00659360 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer NCT00478426 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissu NCT00390234 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma NCT00245102 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer NCT00114218 | Gynecologic Oncology Group | Phase 2 |
| Completed | Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer NCT00238121 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer NCT00075400 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus NCT00025506 | National Cancer Institute (NCI) | Phase 2 |